golidocitinib
dizal pharmaceuticals
['lymphoma', 'jackpot8', 'pivot,io,i', 'pivotal study', 'ptcl', 'dizal']
we are pleased to share that data from the multinational pivotal study (jackpot8) of golidocitnib, a fisrt-in-class jak1 only inhibitor for refractory or relapsed peripheral t cell lymphoma (r/r ptcl), was presented in today's oral session at #asco23.
#ptcl #lymphoma #hematology 
Dizal is a clinical stage, biopharmaceutical company dedicated to differentiated therapeutics for the treatment of cancer and immunological diseases.